Article Text

Download PDFPDF

291 Frequency of pathogenic mutations and prognostic impact of germline gene panel testing in patients with primary epithelial ovarian cancer
  1. B Ataseven1,2,
  2. P Harter1,
  3. K Rhiem3,
  4. F Heitz1,4,
  5. S Schneider1,
  6. M Bommert1,
  7. A Traut1,
  8. RK Schmutzler3 and
  9. A Du Bois1
  1. 1Evang. Huyssens-Stiftung Essen-Huttrop (eine Einrichtung der KEM | Evang. Kliniken Essen-Mitte gGmbH), Gynaecology and Gynaecologic Oncology, Essen, Germany
  2. 2University Hospital, LMU Munich, Department of Obstetrics and Gynecology
  3. 3University Hospital Cologne, Medical Faculty, , Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), , Köln, Germany
  4. 4Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin,, Department for Gynecology with the Center for Oncologic Surgery Charité Campus Virchow-Klinikum, Berlin


Introduction/Background*The detection of gBRCA1/2 mutations in patients (pts) with epithelial ovarian cancer (EOC) provides information regarding family risk and influences clinical management, e.g. use of PARP inhibitors. The availability of next generation sequencing (NGS) allows for simultaneous sequencing of multiple cancer risk genes including BRCA1/2. Our aim was to evaluate the prevalence and clinical outcome of deleterious germline mutations in EOC patients.

Methodology EOC patients treated between 2011 and 2020 at our institution and with germline TruRisk® gene panel testing were included in this retrospective analysis. Based on the genetic test result three cohorts were considered: A) no mutation, B) gBRCA1/2, and C) mutations in other risk genes. Demographic and clinicopathological characteristic were retrieved from the prospective database. To evaluate survival outcome in FIGO III/IV EOC univariate and multivariate logistic regression was performed.

Result(s)*In total 702 EOC pts underwent germline panel testing. Median age was 59 years, 74.5% underwent primary debulking surgery, 83.9% were FIGO III/IV, and complete macroscopic resection was achieved in 74.0%. No mutation was detected in 76.6% (n=538), pathogenic gBRCA1/2 mutations in 17.4% (n=122), and mutations in other risk genes in 6.0% (n=42), respectively (tbl.1). Significant differences between the cohorts were detected for age, pervious history of malignancies, personal/familial breast/ovarian cancer history, and histology.

For FIGO III/IV patients median PFS was significantly different for cohort A, B, and C with 23, 37, and 34 months (p=0.059/multivariate 0.015), respectively. 3-years-OS was 70%, 83%, and 87% for cohorts A, B, and C (p=0.003), respectively.

In multivariate analysis type of surgery (IDS: HR 2.79(1.86-4.19), p<0.001),) ascites >500mL (HR 1.75(1.14-2.68), p=0.010), and residual disease (RD>0mm: HR 2.87(1.99-4.14), p<0.001), were identified as worse prognostic factors for OS. Patients from cohorts B and C showed significantly better OS than those from cohort A (B: HR 0.49(0.31-0.80), p=0.004; C: HR 0.34(0.14-0.85), p=0.021) (table 1, figure 1).

Abstract 291 Figure 1

Overall survival in patients with EOC undergoing cytoreductive surgery broken-down by gene panel analysis/pathogenic mutation status

Abstract 291 Table 1

Univariate and multivariate analysis of prognostic factors for overall survival (OS)

Conclusion*The detection rate of germline mutations in EOC is 23.4%. Our findings underline the necessity to offer germline panel testing in EOC to identify families at risk. Further, our findings underscore the prognostic value of germline mutations towards a better prognosis.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.